CYAD-101 CRC Trial Receives Clinical Hold Following Discussion With FDA

Article

A clinical hold has been placed on the phase 1b CYAD-101-002 trial, examining pembrolizumab after treatment with CYAD-101 and folinic acid, fluorouracil, and oxaliplatin preconditioning in metastatic colorectal cancer.

The phase 1b CYAD-101-002 trial (NCT04991948), assessing pembrolizumab (Keytruda) after treatment with CYAD-101 and folinic acid, fluorouracil, and oxaliplatin (FOLFOX) preconditioning in metastatic colorectal cancer (CRC), received a clinical hold following discussion with the FDA due to the need to assess risk in patients, according to a press release from Celyad Oncology.1

The study was paused voluntarily with the intent of examining 2 reported fatalities that took place on the study.

The open label study had an estimated enrollment of 34 patients. The primary end points are occurrence of dose-limiting toxicities and objective response rate. Enrollment required patients to have histologically confirmed metastatic adenocarcinoma of the colon or rectum and an ECOG performance status of 0 or 1. A tumor biopsy at screening and adequate organ, hepatic, renal, pulmonary, and cardiac function were also required.

The first-in-class, non-gene edited allogeneic CAR T-cell product was previously assessed in the phase 1 AlloSHRINK study (NCT03692429) in a population of patients with unresectable metastatic CRC.2 Of the 15 patients who received CYAD-101 after FOLFOX, confirmed partial responses were reported in 2 patients, 1 of whom had a KRAS mutation. Stable disease was reported in 9 patients, with 7 patients having stable disease that lasted for at least 3 months. The median progression-free survival was 3.9 months.

CYAD-101 was administered as 3 infusions following a standard preconditioning cycle of FOLFOX. A 3+3 dose-escalation format was used, with doses including 108, 3x108, and 109 T cells per infusion.

Investigators did not observe any dose-limiting toxicities, grade 3 or higher adverse effects, or graft-versus-host disease following CYAD-101 infusion.

“These clinical results demonstrate the safety and tolerability of a first-in-human non-gene edited allogeneic CAR T-cell treatment with early promising anti-tumor activity in [patients with advanced metastatic] CRC. Preliminary translational analysis present intriguing observations that the modulation of systemic cytokine levels may be associated with dose which is uncommon in CAR T-cell therapies reported to date while limited T-cell clonal diversification in the best responding patient underscores the likely central role of the adoptively transferred T-cell in driving therapeutic response in this particular patient,” the investigators concluded.

References

  1. Celyad Oncology announces clinical hold of CYAD-101-002 phase 1b trial. News release. Celyad Oncology. March 2, 2022. Accessed March 2, 2022. https://yhoo.it/36Q8DJv
  2. Prenen H, Dekervel J, Hendlisz A, et al. Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC. J Clin Oncol. 2021;39(suppl 3):74-74. doi:10.1200/JCO.2021.39.3_suppl.74

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content